Pfizer names David M. Denton as CFO effective May 2, 2022

PFIZER INC

David M. Denton named CFO, EVP effective May 2, 2022, succeeding Frank D'Amelio after 15-year career.
Compensation: $1.25M base salary, $1.25M target cash incentive (pro-rated for 2022).
One-time $5M cash payment (repayable if voluntary resignation within 1 year), RSUs valued at $3.25M, and $9.75M Supplemental Plan credit.
Denton brings 20+ years healthcare experience; previously CFO at Lowe's and CVS Health.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Frank D'Amelio

Chief Financial Officer and Executive Vice President

PFE · PFIZER INC

Effective: 2022-05-02
Successor: David M. Denton
Filed: April 12, 2022, 7:59 PM ET

As previously reported by the Company in a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 19, 2021, the Company announced that Frank D’Amelio will be leaving his position as Chief Financial Officer and Executive Vice President after a nearly 15-year distinguished career with the Company and that Mr. D’Amelio would continue to serve as CFO until the appointment of a new chief financial officer, and will stay on as a special advisor until as late as December 31, 2022 in order to ensure a smooth transition of his CFO responsibilities.

Appointed

David M. Denton

Chief Financial Officer, Executive Vice President

PFE · PFIZER INC

Effective: 2022-05-02
Filed: April 12, 2022, 7:59 PM ET

On April 11, 2022, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company elected David M. Denton as Chief Financial Officer, Executive Vice President of the Company and appointed Mr. Denton as a member of the Company's Executive Leadership Team, effective May 2, 2022 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Frank D'Amelio departed as Chief Financial Officer and Executive Vice President at PFIZER INC.

Action: leaving
Role: Chief Financial Officer and Executive Vice President

Exact text from the filing

As previously reported by the Company in a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 19, 2021, the Company announced that Frank D’Amelio will be leaving his position as Chief Financial Officer and Executive Vice President after a nearly 15-year distinguished career with the Company and that Mr. D’Amelio would continue to serve as CFO until the appointment of a new chief financial officer, and will stay on as a special advisor until as late as December 31, 2022 in order to ensure a smooth transition of his CFO responsibilities.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David M. Denton was elected as Chief Financial Officer, Executive Vice President at PFIZER INC.

Action: elected
Role: Chief Financial Officer, Executive Vice President

Exact text from the filing

On April 11, 2022, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company elected David M. Denton as Chief Financial Officer, Executive Vice President of the Company and appointed Mr. Denton as a member of the Company's Executive Leadership Team, effective May 2, 2022 (the “Effective Date”).

View on SEC.gov

PFIZER INC filing history →

Source: SEC EDGAR

accession 0000078003-22-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.